Hormone signaling research · Two distinct substances
Make hormone research easier to separate from the sales pitch.
CJC-1295 and ipamorelin are frequently discussed together in growth-hormone conversations. A paired name does not mean an approved combination exists or that the two share one evidence base. Explore what FDA says about their safety and compounding records and why a treatment discussion needs more than a performance or healthy-aging promise.
Educational topic · This is not an offered treatment or trial-access program.
Research & evidence
Clear prices. A clearer next step.
Explore the research. Understand the price context.
The research-market figure below is educational context. Neither a free account nor optional membership purchases access to this compound.
Estimated research-market price · not a treatment offer
CJC-1295 & Ipamorelin blend · research market context
Est. $80per 10 mg laboratory research vial
Single selected public supplier listing. This is research-market context, not a clinical drug quote, treatment cost or purchase offer.
Research-material market context only. Seine Bio does not sell lyophilized powders for self-reconstitution or offer this research compound. This figure does not price a finished clinical product; any lawful treatment requires its own quote. Membership does not provide the named investigational compound.
Discuss my care optionsPrice sources & what is included
Public research-material listings reviewed October 7, 2026. Prices and stock can change; taxes and shipping may be additional. These source links document laboratory listings, not patient-use products, supplier quality or lawful clinical availability.
Optional product-savings membership
Start with a personal care conversation.
$20Per month · Cancel anytime
- 2% off products; therapy services and membership dues excluded
- Free two-business-day shipping after dispatch on $100+ physical-product orders before discounts and taxes in the contiguous United States
- Cancel anytime to stop future membership renewals
Medication, labs, products and additional treatment cost extra. Care is subject to clinical fit and availability. Membership does not guarantee a prescription, named peptide or research enrollment.
Create a free account ↗The context behind the conversation
CJC-1295 & Ipamorelin Research.
A clearer overview.
Research information is not treatment access.
Research education. No approved combination or verified Seine Bio supply pathway is offered.
The biological question.
These are two distinct substances discussed around growth-hormone signaling. A mechanism-based rationale for combining them is not evidence that a particular mixture provides a useful patient benefit. The actual ingredient identity, formulation and route must be clear. Evidence concerning another growth-hormone intervention, including sermorelin or somatropin, cannot simply establish effectiveness or safety for a CJC-1295/ipamorelin combination.
The story behind the name.
The substances have appeared in wellness and performance discussions while their regulatory paths remain separate. CJC-1295 and the 503A ipamorelin nominations are described among withdrawn submissions on FDA’s current page; ipamorelin remains in Category 2 under the 503B interim policy. A business should not collapse those distinctions into a general “doctor-approved peptide” label. The ability to request a clinical consultation is separate from an actual lawful supply route.
FDA’s current safety material describes limited clinical information for CJC-1295 and identifies serious events associated with it, including increased heart rate and a systemic vasodilatory reaction. For ipamorelin, FDA notes serious events in a study involving intravenous administration for gastric motility and insufficient safety information for certain other injectable routes. That distinction should be preserved: events in one studied context do not quantify every other route’s risk, but an absence of route-specific information does not establish safety either. No approved combination benefit claim was verified here.
Understand the evidence
Understanding doses
and cycles.
A clear reference for your conversation with a clinician.
Research doses describe a specific study, not a treatment plan. Online popularity does not establish safety.
| Preparation / context | Dose reference | Frequency | Duration / cycle | Evidence & source |
|---|---|---|---|---|
| CJC-1295 / ipamorelin blend; marketed no-DAC variants | No validated combined human dose | Not established | No validated human on/off wellness cycle | Product and route limitations DAC CJC-1295 and intravenous ipamorelin trials do not establish a daily subcutaneous blend regimen. Read the source |
Swipe or scroll sideways to see every column. There is no universal peptide cycle. A published trial, a product label and an informal online protocol are different kinds of information.
Sources reviewed October 7, 2026. A dose listed here does not establish availability or suitability through Seine Bio.
Discuss my optionsA useful conversation includes the limits
Know the concerns.
Understand the criteria.
These are key considerations, not a complete safety assessment.
Risks & uncertainties
What deserves attention.
- FDA describes peptide-impurity and potential immune-reaction concerns for these substances.
- CJC-1295 has reports of increased heart rate and systemic vasodilatory reaction.
- Ipamorelin’s route-specific safety information is incomplete; the cited intravenous study raised serious safety concerns.
- A combination cannot be presumed safe or effective from separate mechanism discussions.
Clinical & regulatory context
Where this pathway fits.
- No purchase or qualifying treatment path exists for this combination here.
- Each ingredient’s identity and regulatory pathway needs separate review.
- A future offer would require verified product, pharmacy, clinical scope and legal arrangements.
- Fatigue, sleep or body-composition concerns can warrant assessment without assuming this combination is appropriate.
A thoughtful way forward
Learning is a useful first step.
Begin with your questions.
Read the current FDA ingredient-specific safety information.
Understand the evidence.
Separate the compound, route and outcome behind any research claim.
Clarify your next step.
Explore appropriate available clinical evaluation for the concerns that prompted your interest.
Educational topic · This is not an offered treatment or trial-access program.
Create a free account ↗Clear answers before you decide
Your questions.
A clearer starting point.
Take a moment to understand the practical differences, limits and next steps.
Is the combination FDA-approved?
No approved CJC-1295/ipamorelin combined product was verified. This page is educational and does not offer a purchasable injection program. A familiar pairing in wellness marketing does not establish product approval.
Are the two compounding records identical?
No. FDA’s current page distinguishes withdrawn 503A nominations from ipamorelin’s Category 2 status under the 503B interim policy. The exact substance and legal pathway need to be assessed rather than inferred from a general peptide label.
Can research on sermorelin prove this combination works?
No. Different compounds and mixtures need their own relevant evidence. A shared discussion of growth-hormone signaling is not enough to transfer clinical outcomes, safety or an approved indication from one intervention to another.
Can I join membership to get this stack?
No access is confirmed or offered. Research information is free to read. If your goal is help with symptoms, ask about actual assessment services and available options before purchasing membership on the expectation of a specific unverified combination.
Your next step, made simple
Bring your questions.
Find your next step.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
- Research questions and established care options
- Clear availability and costs before you decide
- Personal health history shared through private clinical intake
This is a consultation inquiry, not an order for this compound or a request for guaranteed research access. Clinical suitability and any separate costs are confirmed later.
Start with a free account.
Optional membership: $20/month.
Optional · $20/month · Cancel anytime. Medications, labs, products, additional therapy and separately priced treatments cost extra.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Please keep medical history, medications and sensitive personal details for private clinical intake.
Read beyond the headline
The sources.
Your own closer look.
Follow the original research, prescribing information and official regulatory sources used for this page.
Reviewed October 7, 2026. Evidence and regulatory status can change.
Your next step.Understand your options first.
Create a free accountIndividual care decisions belong to a licensed clinician. Program information does not guarantee a prescription, named compound, appointment, clinical-trial enrollment or product availability. Clinical care requires appropriate licensing, assessment and follow-up. Membership does not replace clinical eligibility.
We do not provide emergency services. For immediate danger or a medical emergency, call 911. For a mental health crisis in the U.S., call or text 988.
Lifestyle imagery is illustrative, not a patient testimonial.